Search Results - "Alcalá Escriche, María José"

Efficacy and safety of ustekinumab in real clinical practice. Retrospective multicentre study. ARAINF cohort by Casas Deza, Diego, García López, Santiago, Lafuente Blasco, Miguel, Vicente Lidón, Raquel, Nerín de la Puerta, Juan, Peña Gonzalez, Elena, Ber Nieto, Yolanda, Charro Calvillo, Mara, Alcalá Escriche, María José, Gomollón García, Fernando, Arroyo Villarino, Maite

“…Ustekinumab, a monoclonal antibody that blocks interleukins 12/23, has proven in clinical trials its efficacy in inducing and maintaining clinical remission of…”
Get more information

Clinical value of CT-P13 trough levels, an infliximab biosimilar, in the management of inflammatory bowel disease by Elosua González, Alfonso, Sanz Segura, Patricia, Oyón Lara, Daniel, López García, Santiago, Arroyo Villarino, Maria Teresa, Alcalá Escriche, Maria José, Ollero Domenche, Leticia, Rodríguez Gutiérrez, Cristina, Nantes Castillejo, Óscar

“…CT-P13 is a biosimilar drug of infliximab (IFX), effective in patients with inflammatory bowel disease (IBD). The monitoring of levels of IFX and anti-IFX…”
Get more information

Efficacy and safety of ustekinumab in real clinical practice. Retrospective multicentre study. ARAINF cohort by Casas Deza, Diego, García López, Santiago, Lafuente Blasco, Miguel, Vicente Lidón, Raquel, Nerín de la Puerta, Juan, Peña Gonzalez, Elena, Ber Nieto, Yolanda, Charro Calvillo, Mara, Alcalá Escriche, María José, Gomollón García, Fernando, Arroyo Villarino, Maite

“…Ustekinumab, a monoclonal antibody that blocks interleukins 12/23, has proven in clinical trials its efficacy in inducing and maintaining clinical remission of…”
Get full text

A booster dose of SARS-COV-2 vaccine improves suboptimal seroconversion rates in patients with inflammatory bowel disease. Results of a prospective multicenter study of GETECCU (VACOVEII study) by Casas Deza, Diego, Julián Gomara, Ana Belén, Caudevilla Biota, Eva, Beltrán, Belén, Domènech, Eugeni, Gutiérrez Casbas, Ana, Mañosa, Miriam, Zabana, Yamile, Roc Alfaro, Lourdes, Valverde Romero, Emilio, García González, Elena, Sicilia, Beatriz, Laredo, Viviana, Alcalá Escriche, Maria José, Madero Velázquez, Lucia, Ferreiro-Iglesias, Rocío, Palmero Pérez, Antonia, Calafat, Margalida, Rubio Iturria, Saioa, Moraleja Yudego, Irene, Ber Nieto, Yolanda, García Mateo, Sandra, P Gisbert, Javier, Vicente Lidón, Raquel, Arias, Lara, Alfambra, Erika, Doñate Borao, Ana Belén, Peña González, Elena, Corsino Roche, Pilar, Vicuña Arregui, Miren, Elorza, Ainara, Domínguez Cajal, Manuel, Chaparro, María, Barreiro-de Acosta, Manuel, García-López, Santiago

“…The response to SARS-CoV-2 vaccination decreases in inflammatory bowel disease (IBD) patients, specially under anti-TNF treatment. However, data on medium-term…”
Get more information

A booster dose of SARS-COV-2 vaccine improves suboptimal seroconversion rates in patients with inflammatory bowel disease. Results of a prospective multicenter study of GETECCU (VACOVEII study) by Casas Deza, Diego, Julián Gomara, Ana Belén, Caudevilla Biota, Eva, Beltrán, Belén, Domènech, Eugeni, Gutiérrez Casbas, Ana, Mañosa, Miriam, Zabana, Yamile, Roc Alfaro, Lourdes, Valverde Romero, Emilio, García González, Elena, Sicilia, Beatriz, Laredo, Viviana, Alcalá Escriche, Maria José, Madero Velázquez, Lucia, Ferreiro-Iglesias, Rocío, Palmero Pérez, Antonia, Calafat, Margalida, Rubio Iturria, Saioa, Moraleja Yudego, Irene, Ber Nieto, Yolanda, García Mateo, Sandra, P. Gisbert, Javier, Vicente Lidón, Raquel, Arias, Lara, Alfambra, Erika, Doñate Borao, Ana Belén, Peña González, Elena, Corsino Roche, Pilar, Vicuña Arregui, Miren, Elorza, Ainara, Domínguez Cajal, Manuel, Chaparro, María, Barreiro-de Acosta, Manuel, García-López, Santiago

“…The response to SARS-CoV-2 vaccination decreases in inflammatory bowel disease (IBD) patients, specially under anti-TNF treatment. However, data on medium-term…”
Get full text

Impact of mesalazine on the response to COVID-19 vaccination in patients with inflammatory bowel disease: Results of a prospective multicentre study of GETECCU (VACOVEII study) by Casas Deza, Diego, Julián Gomara, Ana Belén, Caudevilla Biota, Eva, Beltrán, Belén, Domènech, Eugeni, Gutiérrez Casbas, Ana, Mañosa, Miriam, Zabana, Yamile, Roc Alfaro, Lourdes, Valverde Romero, Emilio, García González, Elena, Sicilia, Beatriz, Laredo, Viviana, Alcalá Escriche, Maria José, Madero Velázquez, Lucia, Ferreiro-Iglesias, Rocío, Palmero Pérez, Antonia, Calafat, Margalida, Rubio Iturria, Saioa, Moraleja Yudego, Irene, Ber Nieto, Yolanda, García Mateo, Sandra, Gisbert, Javier P., Vicente Lidón, Raquel, Arias, Lara, Alfambra, Erika, Doñate Borao, Ana Belén, Peña González, Elena, Corsino Roche, Pilar, Vicuña Arregui, Miren, Elorza, Ainara, Domínguez Cajal, Manuel, Chaparro, María, Barreiro-de Acosta, Manuel, García-López, Santiago

“…The recommendations of the Spanish Ministry of Health on vaccination in risk groups include mesalazine among the treatments with a possible negative effect on…”
Get full text

Clinical value of CT-P13 trough levels, an infliximab biosimilar, in the management of inflammatory bowel disease by Elosua González, Alfonso, Sanz Segura, Patricia, Oyón Lara, Daniel, López García, Santiago, Arroyo Villarino, Maria Teresa, Alcalá Escriche, Maria José, Ollero Domenche, Leticia, Rodríguez Gutiérrez, Cristina, Nantes Castillejo, Óscar

“…CT-P13 is a biosimilar drug of infliximab (IFX), effective in patients with inflammatory bowel disease (IBD). The monitoring of levels of IFX and anti-IFX…”
Get full text